Recently, a variety of agents, including abiraterone, cabazitaxel, and enzalutamide, have been approved in Japan for patients with metastatic castration-resistant prostate cancer (CRPC). [1][2][3] Some patients, however, have already received all these agents and need a different systemic therapy. The novel agent olaparib (Lynparza, AstraZeneca) is a poly ADP-ribose polymerase inhibitor that was recently approved for the treatment of metastatic CRPC in patients harboring BRCA1/2 mutations.